share_log

Predictmedix Expands on Non-Invasive AI-powered Impairment Detection Technology for Vertical-Specific Applications

Predictmedix Expands on Non-Invasive AI-powered Impairment Detection Technology for Vertical-Specific Applications

Predictmedix 扩展了适用于垂直特定应用的非侵入性人工智能驱动的损伤检测技术
Accesswire ·  2023/03/23 19:06

TORONTO, ON / ACCESSWIRE / March 23, 2023 / Predictmedix Inc. ("Predictmedix" or the "Company") (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI) is excited to announce an update on the functionality and application of their technology across specific verticals. The update comes after the Company's recent announcement of the US Patent Grant for its AI-powered technology (United States Patent Application Number: 16/892,369) for the non-invasive detection of impairment caused by alcohol and/or cannabis.

安大略省多伦多/ACCESSWIRE/2023 年 3 月 23 日/ 由专有人工智能(AI)提供支持的快速健康筛查解决方案的领先提供商Predicmedix Inc.(“Predicmedix” 或 “公司”)(CSE: PMED)(OTCQB: PMEDF)(FRA: 3QP)很高兴地宣布其技术在特定垂直领域的功能和应用的最新情况。该更新是在该公司最近宣布其人工智能技术(美国专利申请号:16/892,369)获得美国专利授予之后发布的,该技术用于非侵入性检测酒精和/或大麻造成的损伤。

Predictmedix has achieved over 90% accuracy in identifying impaired individuals using a combination of multispectral imaging and speech analysis, as demonstrated in the Company's latest study. As the technology is powered by artificial intelligence, its accuracy rate is only expected to increase with time, thanks to the deep learning and machine learning algorithms that allow the system to learn and adapt from new data.

正如该公司的最新研究所证明的那样,Predictmedix使用多光谱成像和语音分析相结合识别受损个体的准确率已达到90%以上。由于该技术由人工智能提供支持,其准确率预计只会随着时间的推移而提高,这要归功于深度学习和机器学习算法,使系统能够从新数据中学习和适应。

The patent outlines the process of how data gathered from multispectral imaging and speech analysis is used for identification of impairment. This involves the capture of data by a multispectral camera along with a speech sample. Features and their intensities are extracted and correlated with impairment, with each feature generating an intensity representation. At least one impairment analytical model is then applied to determine a respective impairment likelihood, and a confidence level is determined for each impairment likelihood based on the characteristics associated with at least the applied impairment analytical model and that feature.

该专利概述了如何使用从多光谱成像和语音分析中收集的数据来识别损伤的过程。这涉及通过多光谱摄像机捕获数据以及语音样本。提取特征及其强度并将其与损伤相关联,每个特征都会生成强度表示。然后应用至少一个减值分析模型来确定相应的减值可能性,并根据至少与应用的减值分析模型和该特征相关的特征确定每种减值可能性的置信水平。

With the use of impairing substances, individuals can be unable to safely perform certain tasks. For example, the use of drugs such as cannabis or alcohol can impair an individual's physiological and/or psychological state, leading to significant safety risks. Predictmedix's technology functions by identifying signs of impairment and correlating them with various levels of impairment-inducing agents. Furthermore, the AI algorithms can even identify if someone has consumed just one "standard alcoholic beverage," which may or may not be classified as impaired depending on the jurisdiction. The company offers flexibility for end-users to define the thresholds used to flag someone as impaired or not, based on internal policies and/or the jurisdiction they are operating in.

使用有害物质后,个人可能无法安全地执行某些任务。例如,使用大麻或酒精等药物会损害个人的生理和/或心理状态,从而导致重大安全风险。Predictmedix的技术的作用是识别损伤迹象并将其与各种水平的损伤诱发剂关联起来。此外,人工智能算法甚至可以识别某人是否只饮用了一种 “标准酒精饮料”,根据司法管辖区的不同,该饮料可能会被归类为受损饮品,也可能不被归类为受损饮品。该公司为最终用户提供了灵活性,使他们可以根据内部政策和/或运营所在的司法管辖区来定义用于将某人标记为是否受损的阈值。

The patented technology will also be used in Predictmedix's AI-powered mobile app, which works alongside a portable multispectral imaging camera for non-invasive impairment detection. The company plans to commercialize its mobile solution to serve global law enforcement agencies, transport, and other high-risk industries where impairment is a significant liability.

该专利技术还将用于Predictmedix的人工智能移动应用程序,该应用程序与便携式多光谱成像相机一起使用,用于非侵入性损伤检测。该公司计划将其移动解决方案商业化,为全球执法机构、运输和其他高风险行业提供服务,在这些行业中,减值是重大负债。

According to industry reports, the global workplace safety market is expected to experience significant growth in the coming years, with a projected value of $39 billion by 2031.1 Additionally, the drug screening market is expected to reach nearly $22.24 billion with a CAGR of 15.97% from 2022 to 2029.2 With Predictmedix's expansion on its non-invasive impairment detection technology, the company is well-positioned to capture a significant portion of this growing market. By providing innovative solutions to high-risk industries, Predictmedix aims to improve workplace safety and help prevent accidents caused by impairment.

根据行业报告,预计未来几年全球工作场所安全市场将实现显著增长,预计到2031年将达到390亿美元。1 此外,预计从2022年到2029年,药物筛查市场将达到近222.4亿美元,复合年增长率为15.97%。2 随着Predictmedix扩展其非侵入性损伤检测技术,该公司完全有能力占领这个不断增长的市场的很大一部分。通过为高风险行业提供创新的解决方案,Predictmedix旨在改善工作场所安全并帮助预防由损伤造成的事故。

"We are thrilled to announce the expansion of our non-invasive impairment detection technology for vertical-specific applications. With this cutting-edge technology, we can detect impairment caused by alcohol and/or cannabis, helping mitigate safety risks in high-risk industries such as law enforcement and transportation. We are excited to continue working towards the commercialization of our mobile solution, providing a safer environment for workers and the public. Predictmedix is committed to leveraging our proprietary artificial intelligence to offer efficient and reliable health screening solutions, and we look forward to introducing our technology to new industries in the future," commented Dr. Rahul Kushwah, Chief Operating Officer at Predictmedix.

“我们很高兴地宣布,我们的非侵入性损伤检测技术已扩展到垂直特定应用。借助这项尖端技术,我们可以检测酒精和/或大麻造成的损害,帮助降低执法和运输等高风险行业的安全风险。我们很高兴能继续努力实现移动解决方案的商业化,为员工和公众提供更安全的环境。Predictmedix致力于利用我们专有的人工智能来提供高效可靠的健康筛查解决方案,我们期待将来将我们的技术引入新行业。” Predictmedix首席运营官Rahul Kushwah博士评论道。

1

1

2

2

About Predictmedix Inc.

关于 Predicmedix Inc.

Predictmedix (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue or various mental illnesses. Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn.

Predicmedix(CSE:PMED)(OTCQB:PMEDF)(FRA: 3QP)是全球快速健康筛查和远程患者护理解决方案的新兴提供商。该公司的安全进入站由专有的人工智能(AI)提供支持,使用多光谱摄像机分析生理数据模式并预测各种健康问题,包括 COVID-19 等传染病、药物或酒精损伤、疲劳或各种精神疾病。Predictmedix 专有的远程患者护理平台为医疗专业人员提供了一套人工智能驱动的工具,以改善患者的健康状况。要了解更多信息,请访问我们的网站或在推特、Instagram 或 LinkedIn 上关注我们。

Public Relations Contact
For further media information or to set up an interview, please contact:
Nelson Hudes
Hudes Communications International
(905) 660 9155
Nelson@hudescommunications.com

公共关系联系人
欲了解更多媒体信息或安排采访,请联系:
纳尔逊·哈德斯
Hudes 通讯国际
(905) 660 9155
Nelson@hudescommunications.com

Dr. Rahul Kushwah
(647) 889 6916

拉胡尔·库什瓦博士
(647) 889 6916

Caution Regarding Forward-Looking Information:

关于前瞻性信息的注意事项:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

本新闻稿可能包含前瞻性陈述和基于当前预期的信息。这些陈述不应被视为对公司未来业绩或业绩的保证。此类陈述涉及已知和未知的风险、不确定性和其他因素,这些因素可能导致实际业绩、业绩或成就与此类陈述所暗示的结果存在重大差异。尽管此类陈述基于管理层的合理假设,但无法保证此类假设会被证明是正确的。我们不负责更新或修改它们以反映新的事件或情况。公司的证券尚未根据经修订的1933年《美国证券法》(“美国证券法”)或适用的州证券法进行注册,如果没有注册或不受此类注册要求的适用豁免,则不得向在美国的人或 “美国个人”(该术语的定义见美国证券法的法规)发行或出售,也不得为他们的账户或利益发行或出售。本新闻稿不构成出售要约或招揽买入要约,也不得在美国或任何此类要约、招揽或出售非法的司法管辖区出售证券。此外,还有一些已知和未知的风险因素可能导致公司的实际业绩、业绩或成就与本文件所含前瞻性信息所表达或暗示的未来业绩、业绩或成就存在重大差异,例如但不限于依赖获得监管部门批准;获得与其技术相关的知识产权的能力;运营历史有限;一般商业、经济、竞争、政治、监管和社会不确定性,以及特别是与 COVID-19 相关的不确定性;与公司无法控制的因素相关的风险,包括与 COVID-19 相关的风险;与公司股票相关的风险,包括该方可能也可能无法控制的事件导致的价格波动;对管理层的依赖;以及该行业其他竞争对手的紧急情况。

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

本文中的所有前瞻性信息均受本警示声明的全面限制,除非法律要求,否则公司不承担任何修改或更新任何此类前瞻性信息或公开宣布为反映未来业绩、事件或发展而对本文包含的任何前瞻性信息进行任何修订的结果的义务。

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."

免责声明:“公司目前没有明示或暗示地声称其产品能够诊断、消除、治愈或控制 COVID-19(或 SARS-2 冠状病毒)。”

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

加拿大证券交易所尚未审查本新闻稿的充分性或准确性,也不承担任何责任。

SOURCE: PredictMedix Inc.

来源: predicmedix Inc.


View source version on accesswire.com:
在 accesswire.com 上查看源代码版本:

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发